Procaps Group S.A.

NasdaqGM:PROC Stock Report

Market Cap: US$77.8m

Procaps Group Valuation

Is PROC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PROC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PROC ($0.69) is trading below our estimate of fair value ($1.93)

Significantly Below Fair Value: PROC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PROC?

Key metric: As PROC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PROC. This is calculated by dividing PROC's market cap by their current earnings.
What is PROC's PE Ratio?
PE Ratio1.5x
EarningsUS$52.20m
Market CapUS$77.85m

Price to Earnings Ratio vs Peers

How does PROC's PE Ratio compare to its peers?

The above table shows the PE ratio for PROC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.8x
ORMP Oramed Pharmaceuticals
20.1x-163.0%US$89.9m
ETST Earth Science Tech
18.4xn/aUS$41.9m
BTMD biote
23.3x62.1%US$195.8m
IBO Impact BioMedical
29.5xn/aUS$34.4m
PROC Procaps Group
1.5xn/aUS$77.8m

Price-To-Earnings vs Peers: PROC is good value based on its Price-To-Earnings Ratio (1.5x) compared to the peer average (22.8x).

Price to Earnings Ratio vs Industry

How does PROC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.19.1x23.8%
PROC Procaps Group
 1.5xn/aUS$77.85m
OGN Organon
3x-7.1%US$3.87b
NDOI Endo
0.6xn/aUS$1.91b
PROC 1.5xIndustry Avg. 19.1xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
Industry Avg.19.1x23.8%
PROC Procaps Group
 1.5xn/aUS$77.85m
No more companies

Price-To-Earnings vs Industry: PROC is good value based on its Price-To-Earnings Ratio (1.5x) compared to the US Pharmaceuticals industry average (19.1x).

Price to Earnings Ratio vs Fair Ratio

What is PROC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PROC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PROC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.43

7D

-5.4%

1Y

73.9%

IQVIA Holdings

US$35.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$192.68

7D

-11.2%

1Y

-6.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.58

7D

-8.4%

1Y

10.3%